This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The global human immunodeficiency virus type-1 market is currently in the growth phase of its lifecycle, driven by ongoing advancements in antiretroviral therapies (ART) and increasing global access to treatment. Since the introduction of highly effective ART, the management of HIV-1 has shifted from a fatal diagnosis to a chronic manageable condition. In recent years, the global human immunodeficiency virus type-1 market has been fueled by the introduction of long-acting therapies, dual and triple combination drugs, and the focus on prevention strategies, such as pre-exposure prophylaxis (PrEP).
The rising prevalence of HIV-1, especially in sub-Saharan Africa, alongside a growing awareness of the importance of early diagnosis and treatment, has contributed to an expanding patient base. Additionally, the availability of generics in various regions has significantly reduced treatment costs, leading to broader access to ART. Despite these positive developments, the global human immunodeficiency virus type-1 market still faces challenges, such as the high cost of newer therapies and side effects of long-term ART. However, innovations in treatment adherence, new drug formulations, and vaccine research are expected to propel the global human immunodeficiency virus type-1 market further in the coming years.
The global human immunodeficiency virus type-1 market is thus positioned in a mature growth phase, with continued expansion driven by technological innovations, global access initiatives, and research into a functional cure or HIV vaccines, making it an attractive area for continued investment and innovation.
Impact
- Increasing demand for human immunodeficiency virus type-1 therapies is anticipated to support the growth of the global human immunodeficiency virus type-1 market during the forecast period 2025-2035.
- The global human immunodeficiency virus type-1 market is expected to grow at a significant rate due to the increasing prevalence of the disease, advancements in antiretroviral therapies (ART), and the growing adoption of long-acting treatments that offer more effective and convenient management of HIV. Additionally, the expanding research pipeline, including efforts to develop a functional cure and HIV vaccines, as well as the potential for pre-exposure prophylaxis (PrEP) and non-invasive treatment options, are anticipated to drive the global human immunodeficiency virus type-1 market expansion in the near future.
Market Segmentation:
Segmentation 1: by Drug Class
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Protease Inhibitors (PIs)
- Fusion Inhibitors
- Integrase Strand Transfer Inhibitor (INSTIs)
- Others
Segmentation 2: by Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Rest-of-the-World
Recent Developments in the Global Human Immunodeficiency Virus Type-1 Market
- Partnerships: In October 2024, Dr. Reddy’s Laboratories Ltd. entered into an agreement with Gilead Sciences Ireland UC for the manufacture and commercialization of the drug Lenacapavir in India and 120 other countries.
- Product Launch: In August 2023, Aurobindo Pharma Ltd announced the launch of its HIV triple combination product formulated specifically for children living with HIV in low- and middle-income countries, aiming to enhance treatment accessibility and support pediatric HIV care in resource-limited settings.
- Regulatory Approval: In December 2022, the U.S. FDA approved Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with human immunodeficiency virus type 1 (HIV-1). This approval targets patients whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations.
Demand - Drivers and Limitations
The following are the drivers for the global human immunodeficiency virus type-1 market:
- Rising Prevalence and Incidence of Human Immunodeficiency Virus Type-1
- Advancements in Antiretroviral Therapy
- Access to Generics and Lower Treatment Costs
The global human immunodeficiency virus type-1 market is expected to face some limitations too, due to the following challenges:
- High Costs of Advanced Treatments
- Side Effects and Long-Term Adherence
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: Product launches and innovations in the global human immunodeficiency virus type-1 market are focused on advancing treatment options and diagnostic technologies to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of HIV-1. Key players in the market, such as Gilead Sciences and Merck & Co., have been involved in the development of novel therapies, including long-acting injectable treatments and combination regimens, which provide improved adherence and enhanced patient outcomes. Additionally, innovations in HIV-1 diagnostics and prevention strategies such as pre-exposure prophylaxis (PrEP) are helping to reduce the spread of HIV-1 and improve disease management globally.
Competitive Strategy: Enterprises led by market leaders in the global HIV-1 market are continuously updating their product portfolios with innovative, application-specific treatments to maintain competitiveness. Companies are focusing on developing long-acting treatments, combination drugs, and novel prevention strategies to address the evolving needs of HIV-1 patients. A detailed competitive benchmarking of the key players in the global HIV-1 market has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, regulatory approvals, and product launches will help readers identify untapped revenue opportunities in the market.
Key Market Players and Competition Synopsis
The companies that are profiled in the global human immunodeficiency virus type-1 market have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.
The top segment players include human immunodeficiency virus type-1 therapy providers that capture around 95% of the global human immunodeficiency virus type-1 market.
Some of the prominent names established in the global human immunodeficiency virus type-1 market are:
- Gilead Sciences, Inc.
- ViiV Healthcare
- Janssen Pharmaceuticals
- Bristol-Myers Squibb
- AbbVie Inc.
- Merck
- Boehringer Ingelheim
- GlaxoSmithKline
- Theratechnologies Inc.
- Sandoz
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.
Table of Contents
Executive SummaryScope of StudyResearch Methodology
Companies Mentioned
- Gilead Sciences, Inc.
- ViiV Healthcare
- Janssen Pharmaceuticals
- Bristol-Myers Squibb
- AbbVie Inc.
- Boehringer Ingelheim
- GlaxoSmithKline
- Merck
- Theratechnologies Inc.
- Sandoz
